Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies-Reference-Cited by-同舟云学术

Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

Published:2021-02-28 Issue:4 Volume:14 Page:445-456
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Wang Zeng¹^ORCID,Jiang Liyu²,Yan Hao²,Xu Zhifei²^ORCID,Luo Peihua²

Affiliation:

1. Department of Colorectal Pharmacy, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China

2. Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2021.1894129

Reference98 articles.

1. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

2. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

3. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

4. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia;Leukemia;2024-02-02

2. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors;Journal of the National Comprehensive Cancer Network;2024-02

3. Advances in the Treatment of Chronic Myeloid Leukemia;Recent Patents on Anti-Cancer Drug Discovery;2024-02

4. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib;Annals of Hematology;2023-11-28

5. Asciminib - ABL Kinase Inhibitor in the Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia: Chemistry and Pharmacology Perspectives;Mini-Reviews in Organic Chemistry;2023-10-17